246 related articles for article (PubMed ID: 35575711)
1. Clinical Dose Preparation of [
Menon SR; Mitra A; Chakraborty A; Tawate M; Sahu S; Rakshit S; Gaikwad S; Dhotre G; Damle A; Banerjee S
Cancer Biother Radiopharm; 2022 Jun; 37(5):384-402. PubMed ID: 35575711
[No Abstract] [Full Text] [Related]
2. Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates.
Razumienko EJ; Chen JC; Cai Z; Chan C; Reilly RM
J Nucl Med; 2016 Mar; 57(3):444-52. PubMed ID: 26429962
[TBL] [Abstract][Full Text] [Related]
3. Intricacies in the Preparation of Patient Doses of [
Chakraborty A; Mitra A; Sahu S; Tawate M; Lad S; Kamaldeep ; Rakshit S; Upadhye Bannore T; Gaikwad S; Dhotre G; Ray MK; Damle A; Basu S; Banerjee S
Mol Imaging Biol; 2024 Feb; 26(1):61-80. PubMed ID: 37673943
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic Multidose Preparation of a Ready-to-Use
Chakraborty A; Mitra A; Tawate M; Sahoo S; Lad S; Rakshit S; Gaikwad S; Basu S; Shimpi H; Banerjee S
Cancer Biother Radiopharm; 2021 Oct; 36(8):682-692. PubMed ID: 34402687
[No Abstract] [Full Text] [Related]
5. Development of Lu-177-trastuzumab for radioimmunotherapy of HER2 expressing breast cancer and its feasibility assessment in breast cancer patients.
Bhusari P; Vatsa R; Singh G; Parmar M; Bal A; Dhawan DK; Mittal BR; Shukla J
Int J Cancer; 2017 Feb; 140(4):938-947. PubMed ID: 27813061
[TBL] [Abstract][Full Text] [Related]
6. Formulation of patient dose of [
Amirdhanayagam J; Guleria M; Sharma R; Kumar N; Mukherjee A; Das T
J Labelled Comp Radiopharm; 2024 Apr; 67(4):131-144. PubMed ID: 38342496
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of
Sharma R; Mukherjee A; Kumar A; Sarma HD
Cancer Biother Radiopharm; 2024 Feb; 39(1):64-74. PubMed ID: 38363819
[No Abstract] [Full Text] [Related]
8. Dose-dependent cell cycle arrest and apoptosis in HER2 breast cancer cells by
Sharma R; Kameswaran M; Pandey U; Dash A
J Cancer Res Ther; 2020; 16(6):1426-1434. PubMed ID: 33342808
[TBL] [Abstract][Full Text] [Related]
9. [(177)Lu]pertuzumab: experimental studies on targeting of HER-2 positive tumour cells.
Persson M; Tolmachev V; Andersson K; Gedda L; Sandström M; Carlsson J
Eur J Nucl Med Mol Imaging; 2005 Dec; 32(12):1457-62. PubMed ID: 16193312
[TBL] [Abstract][Full Text] [Related]
10. Bulk Scale Formulation of Therapeutic Doses of Clinical Grade Ready-to-Use
Mathur A; Prashant V; Sakhare N; Chakraborty S; Vimalnath KV; Mohan RK; Arjun C; Karkhanis B; Seshan R; Basu S; Korde A; Banerjee S; Dash A; Sachdev SS
Cancer Biother Radiopharm; 2017 Sep; 32(7):266-273. PubMed ID: 28910148
[TBL] [Abstract][Full Text] [Related]
11. Dual-Receptor-Targeted (DRT) Radiation Nanomedicine Labeled with
Yook S; Cai Z; Jeong JJ; Lu Y; Winnik MA; Pignol JP; Reilly RM
Mol Pharm; 2020 Apr; 17(4):1226-1236. PubMed ID: 32022567
[TBL] [Abstract][Full Text] [Related]
12. Tracer level radiochemistry to clinical dose preparation of (177)Lu-labeled cyclic RGD peptide dimer.
Chakraborty S; Sarma HD; Vimalnath KV; Pillai MR
Nucl Med Biol; 2013 Oct; 40(7):946-54. PubMed ID: 23850487
[TBL] [Abstract][Full Text] [Related]
13. 177Lu labeling of Herceptin and preclinical validation as a new radiopharmaceutical for radioimmunotherapy of breast cancer.
Rasaneh S; Rajabi H; Babaei MH; Daha FJ
Nucl Med Biol; 2010 Nov; 37(8):949-55. PubMed ID: 21055626
[TBL] [Abstract][Full Text] [Related]
14. Preparation of [
Guleria M; Das T; Amirdhanayagam J; Sarma HD; Dash A
Nucl Med Biol; 2019; 78-79():31-40. PubMed ID: 31731177
[TBL] [Abstract][Full Text] [Related]
15. Theranostic pretargeted radioimmunotherapy of internalizing solid tumor antigens in human tumor xenografts in mice: Curative treatment of HER2-positive breast carcinoma.
Cheal SM; Xu H; Guo HF; Patel M; Punzalan B; Fung EK; Lee SG; Bell M; Singh M; Jungbluth AA; Zanzonico PB; Piersigilli A; Larson SM; Cheung NV
Theranostics; 2018; 8(18):5106-5125. PubMed ID: 30429889
[TBL] [Abstract][Full Text] [Related]
16. Radiolabeling of trastuzumab with 177Lu via DOTA, a new radiopharmaceutical for radioimmunotherapy of breast cancer.
Rasaneh S; Rajabi H; Babaei MH; Daha FJ; Salouti M
Nucl Med Biol; 2009 May; 36(4):363-9. PubMed ID: 19423003
[TBL] [Abstract][Full Text] [Related]
17. Preclinical evaluation of 227Th-labeled and 177Lu-labeled trastuzumab in mice with HER-2-positive ovarian cancer xenografts.
Abbas N; Bruland ØS; Brevik EM; Dahle J
Nucl Med Commun; 2012 Aug; 33(8):838-47. PubMed ID: 22643311
[TBL] [Abstract][Full Text] [Related]
18. Preparation of
Pandey U; Kameswaran M; Gamre N; Dash A
J Labelled Comp Radiopharm; 2019 Apr; 62(4):158-165. PubMed ID: 30663095
[TBL] [Abstract][Full Text] [Related]
19. Preparation of
Guleria M; Amirdhanayagam J; Sarma HD; Rallapeta RP; Krishnamohan VS; Nimmagadda A; Ravi P; Patri S; Kalawat T; Das T
Biomed Res Int; 2021; 2021():1555712. PubMed ID: 34845436
[TBL] [Abstract][Full Text] [Related]
20. Gadolinium-Based Nanoparticles Sensitize Ovarian Peritoneal Carcinomatosis to Targeted Radionuclide Therapy.
Garcia-Prada CD; Carmes L; Atis S; Parach A; Bertolet A; Jarlier M; Poty S; Garcia DS; Shin WG; Du Manoir S; Schuemann J; Tillement O; Lux F; Constanzo J; Pouget JP
J Nucl Med; 2023 Dec; 64(12):1956-1964. PubMed ID: 37857502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
